REVIEW

Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors

S Cerquozzi and A Tefferi

Polycythemia vera (PV) and essential thrombocythemia (ET) constitute two of the three *BCR-ABL1*-negative myeloproliferative neoplasms and are characterized by relatively long median survivals (approximately 14 and 20 years, respectively). Potentially fatal disease complications in PV and ET include disease transformation into myelofibrosis (MF) or acute myeloid leukemia (AML). The range of reported frequencies for post-PV MF were 4.9–6% at 10 years and 6–14% at 15 years and for post-ET MF were 0.8–4.9% at 10 years and 4–11% at 15 years. The corresponding figures for post-PV AML were 2.3–14.4% at 10 years and 5.5–18.7% at 15 years and for post-ET AML were 0.7–3% at 10 years and 2.1–5.3% at 15 years. Risk factors cited for post-PV MF include advanced age, leukocytosis, reticulatin fibrosis, splenomegaly and *JAK2V617F* allele burden and for post-ET MF include advanced age, leukocytosis, anemia, reticulatin fibrosis, absence of *JAK2V617F*, use of anagrelide and presence of *ASXL1* mutation. Risk factors for post-PV AML include advanced age, leukocytosis, reticulatin fibrosis, splenomegaly, abnormal karyotype, *TP53* or *RUNX1* mutations as well as use of pipobroman, radiophosphorus (P^{32}) and busulfan and for post-ET AML include advanced age, leukocytosis, anemia, extreme thrombocytosis, thrombosis, reticulatin fibrosis, *TP53* or *RUNX1* mutations. It is important to note that some of the aforementioned incidence figures and risk factor determinations are probably inaccurate and at times conflicting because of the retrospective nature of studies and the inadvertent labeling, in some studies, of patients with prefibrotic primary MF or 'masked' PV, as ET. Ultimately, transformation of MPN leads to poor outcomes and management remains challenging. Further understanding of the molecular events leading to disease transformation is being investigated.

Blood Cancer Journal (2015) 5, e366; doi:10.1038/bcj.2015.95; published online 13 November 2015

INTRODUCTION

Myeloproliferative neoplasms (MPN) are hematopoietic stem cell malignancies characterized by clonal proliferation of myeloid-lineage cells. The four popular (also known as 'classic') MPN are chronic myeloid leukemia, polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF).¹ PV, ET and PMF are operationally referred to as *BCR-ABL1*-negative MPN and are characterized by recurrent *JAK2*, calreticulin (*CALR*) or myeloproliferative leukemia virus oncogene (*MPL*) mutations.

In a recently published study with mature survival data, life-expectancy was significantly compromised in all three *BCR-ABL1*-negative MPN and median survivals for PV and ET were reported at approximately 14 and 20 years, respectively, and in those < 60 years of age at 24 and 30 years.² The International Working Group for MPN Research and Treatment (IWG-MRT) have identified thrombosis history, leukocytosis and advanced age as independent risk factors for overall survival in both PV and ET (Table 1).^{3,4} Disease-related complications affecting survival in both PV and ET include thrombohemorrhagic events and disease transformation into myelofibrosis (MF) or acute leukemia, also known as 'blast phase (BP)' disease. The latter is often in the form of acute myeloid leukemia (AML) although cases of lymphoblastic transformation have been reported.^{5–7} Post-MPN AML has dismal prognosis with median survival of < 6 months and long-term remissions can only

be achieved through allogeneic stem cell transplant.^{8,9} Here we review the reported rates of both fibrotic and leukemic transformation (LT) in PV and ET and the risk factors associated with disease progression.

POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF)

Post-PV MF represents a natural evolution of PV and is defined based on IWG-MRT consensus criteria requiring a history of a World Health Organization (WHO)-diagnosed PV and bone marrow fibrosis grade ≥ 2 (3-point scale) or ≥ 3 (4-point scale). At least two of the following features must also be present: anemia or sustained loss of need for phlebotomy and/or cytoreductive therapy, a leukoerythroblastic peripheral smear, splenomegaly and one or more constitutional symptoms.¹⁰ Less than 10% of PV patients evolve into MF within their first decade with reported incidences shown in Table 2 ranging from 2.3% to 23%.^{2,3,7,11–20} The cumulative incidence of MF evolution is 5–14% at 15 years.^{7,11,17} Interestingly, a recent cohort of Chinese PV patients demonstrated significantly higher 10-, 15- and 20-year incidences of post-PV MF at 27.4, 39.9 and 61.1%, which may suggest that this population of patients are at higher risk of fibrotic transformation.²⁰ Ultimately, transformation to MF shortens PV survival rates (hazards ratio (HR) = 2.17; confidence interval (CI): 1.27–3.72, $P=0.005$), after adjusting for prognostic factors

Table 1. Predicting long-term outcomes for patients with polycythemia vera and essential thrombocythemia

	PV	ET
Overall survival (years)	13.5–24	11–22.6
Leukemic transformation (median time in years)	4.6–19	6.3–14.5
Cumulative risks	— 2.3–14.4% at 10 years 5.5–18.7% at 15 years 7.9–17% at 20 years	0.2–0.3% at 5 years 0.7–3% at 10 years 2.1–5.3% at 15 years 8.1% at 20 years
Myelofibrosis transformation (median time in years)	8.5–20	7.3–16
Cumulative risks	— 4.9–6% at 10 years 6–14% at 15 years 26% at 20 years	0.1–1% at 5 years 0.8–4.9% at 10 years 4–11% at 15 years 19.9% at 20 years
Risk algorithms	IWG-MRT ³ —to predict overall survival	IPSET ⁴ —to predict survival and occurrence of thrombosis
Risk factors		
Age	≥ 67 (5 pts) vs 57–66 (2 pts)	≥ 60 (2 pts)
WBC	≥ 15 × 10 ⁹ /l (1 pt)	≥ 11 × 10 ⁹ /l (1 pt)
Thrombosis	Venous thrombosis (1 pt)	Yes (1 pt)
Category		
Low risk	0 pts	0 pts
Intermediate risk	1–2 pts	1–2 pts
High risk	≥ 3 pts	3–4 pts
Survival (years)		
Low risk	26	NR
Intermediate risk	15	24.5
High risk	8.3	13.8

Abbreviations: ET, essential thrombocythemia; IWG-MRT, International Working Group for MPN Research and Treatment; IPSET, International Prognostic Score for essential thrombocythemia; NR, not reported; pt/pts, patient/patients; PV, polycythemia vera; WBC, white blood cell.

such as age, white blood cell count, hemoglobin level, platelet count and spleen size.²¹ Older age (≥60 years) and leukocytosis (>10 or 15 × 10⁹/l) increases the risk for post-PV MF evolution.^{14,21,22} Based on both retrospective and prospective studies, median time to MF transformation is 8.5–20 years from time of diagnosis.^{2,7,11,14,17–19} PV patients ≤45 years have a longer median time to MF transformation of 20 years compared with transforming in a median 8 years for patients who are ≥65 years.¹⁸ In a large prospective multicentered cohort of 1638 PV patients, 38 (2%) transformed to MF whereby greater duration of disease impacted transformation rates. PV patients with a disease course of 6–10 years had a relative risk of fibrotic transformation of 5.74; 95% CI, 1.51–21.77 and while disease duration >10 years resulted in relative risk of 15.24; 95% CI, 4.22–55.06; *P* < 0.0001.¹³ Additional risk factors for post-PV MF include: presence of baseline bone marrow fibrosis, *JAK2V617* allele burden, splenomegaly, thrombocytosis (platelet count >550 × 10⁹/l) and the presence of a ‘masked PV’ phenotype (display PV-characteristic BM morphology but lower hemoglobin levels than WHO criteria targets).^{15,16,20,23–25} Once transformed to post-PV MF, median survival is drastically shortened to 5.7 years.²¹ Passamonti *et al.*²¹ developed a dynamic prognostic model for patients who developed post-PV MF based on three independent risk factors: hemoglobin <100 g/l, platelet count <100 × 10⁹/l, and leukocyte count >30 × 10⁹/l. The presence of any of these risk factors results in a 4.2-fold increased risk of death. Anemia, at the time of MF transformation, leads to significant differences in survival of 6.6 versus 1.9 years for patients with hemoglobin ≥100 g/l compared with <100 g/l, respectively (*P* < 0.001).²¹ Similarly, among a Chinese cohort, anemia (hemoglobin <100 g/l) and age >65 years significantly predicted worse outcomes, resulting in a 5-year

survival rate of only 17.3% (median 3 years) in post-PV MF patients with both risk factors.²⁰

POST-POLYCYTHEMIA VERA ACUTE MYELOID LEUKEMIA

Based on large multicenter PV patient data, rates of LT in PV are estimated at 2.3% at 10 years, 5.5% at 15 years and remain <10% at 20 years.^{2,3} Higher cumulative incidence rates or actuarial risks of LT of 8–14% at 10 years, 14–19% at 15 years and up to 24% at 18 years have been reported in smaller studies.^{7,17} As outlined in Table 2, LT typically occurs within a median time of 4.6–19 years from initial PV diagnosis.^{2,3,7,11,12,14,17–19} Younger patients (≤45 years) transform to leukemia at a median time of 19 years compared with 7 years for patients aged >65 years, but the difference is not statistically significant (*P* = 0.37). Rates of both MF and LT transformation occur at the same frequency between age groups (15% versus 10%, *P* = 0.29), although, as expected, leukemic development contributed to more deaths in older patients.¹⁸ Factors influencing leukemic-free survival included: age (>61 years³ or ≥70 years),^{12,13} leukocytosis (≥10 × 10⁹/l or ≥15 × 10⁹/l),^{3,7,14} abnormal karyotype,³ splenomegaly, and bone marrow reticulin grade.¹⁶ In the two largest prospective studies including >1500 PV patients, age >61 years (HR 6.3; 95% CI, 1.2–13.1, *P* = 0.03)³ or >70 years (HR 4.30; 95% CI, 1.16–15.94, *P* = 0.0294)¹² and leukocytosis ≥15 × 10⁹/l (HR of 3.9; 95% CI, 1.3–11.6, *P* = 0.0004) adversely impacted LT risk.³ Female sex was a risk factor in a single study by Finazzi *et al.*¹² Lower cholesterol levels (≤150 mg/dl) has been linked to AML/myelodysplastic syndrome (MDS) transformation (HR 6.58; 95% CI, 2.08–20.86, *P* = 0.0014) and is seen in advanced stages of proliferative disease possibly representing a marker of disease activity.^{12,26} Multiple

Table 2. Studies evaluating outcomes in polycythemia vera

	Kiladjian et al. ⁷	Pasamonti et al. ¹¹	Finazzi et al. ¹²	Marchioli et al. ¹³	Gangat et al. ¹⁴	Pasamonti et al. ¹⁵	Abdulkarim et al. ¹⁶	Tefferi et al. ³	Bonicelli et al. ¹⁷	Stein et al. ¹⁸	Sever et al. ¹⁹	Tefferi et al. ²	Bai et al. ²⁰
N	164	396	1638	1638	459	320	150	1545	327	204	133	267 (Mayo) 310 (Italy)	272
Median F/U (years)	11.4	9.6	2.8	2.7	5.3	3.2	15	6.9	11	8 (age ≤ 45 years) 4.5 (age ≥ 65 years)	7.5	11.8 11.1	6
MF													
N	14 (8.5%)	5.1 (3.3–7.8) ^a	NR	38 (2.3%)	54 (12%)	8 (2.5%)	13 (8.5%)	138 (9%)	37 (11%)	26 (12.7%)	11 (8%)	34 (12.7%) 65 (21%)	63 (23%) ^b
Median time to MF from Dx (years)	12.5	13	NR	NR	10.5	NR	NR	NR	9.6	20 (age ≤ 45 years) 8 (age ≥ 65 years)	8.5 ^c	9.6	NR
Risk factors	None	Sequential use of ≥ 2 myelosuppressive agents compared with Pipobroman	NR	Disease duration > 10 years	Age ≥ 60 years	JAK2V617F allele burden ≥ 50%	Splenomegaly Reticulin grading	NR	None	Median age at MF Dx	None	None	Splenomegaly Pit > 550 × 10 ⁹ /l JAK2V617F allele burden ≥ 50%
Leukemia													
N	32 (19.5%)	5.3 (3.5–8) ^a	22 (1.3%)	21 (1.3%)	34 (7.4%)	10 (3%)	13 (8.5%)	50 (3%)	30 (9.2%)	7 (3%)	4 (3%)	18 (6.7%) 10 (3.2%)	6.6 (3.7–10.8) ^d
Median time to LT from Dx (years)	9.6	14	8.4	NR	10.5	NR	NR	10.8	4.6	19 (age ≤ 45 years) 7 (age ≥ 65 years)	8.5 ^c	NR	NR
Risk factors	WBC ≥ 10 × 10 ⁹ /l	Sequential use of ≥ 2 myelosuppressive agents compared with HU or Pipobroman	Age ≥ 70 years P32 Busulphan Pipobroman Cytoinductive drug alone or in combo Low cholesterol (≤ 150 mg/dl)	Age ≥ 70 years Cytoinductive agents other than HU or IFN	WBC ≥ 10 × 10 ⁹ /l WBC ≥ 15 × 10 ⁹ /l	None	Spleno megaly Reticulin grading	Age > 61 years WBC ≥ 15 × 10 ⁹ /l Abnormal karyotype P32/CMB alone Pipobroman	Female	None	None	None	Pit < 100 × 10 ⁹ /l
Median Survival (years)	15.5	20	NR	NR ^e	22.7	NR	NR ^f	18.9 ^g	17.5 (age < 65 years) 6.4 (age ≥ 65 years) ^h	NR	24	13.5 ⁱ	NR ^j
Risk factors	Age ≥ 60 years WBC ≥ 10 × 10 ⁹ /l	Thrombosis	NR	Age > 65 years Thrombosis	Age ≥ 60 years WBC ≥ 15 × 10 ⁹ /l Arterial thrombosis	Age ≥ 60 years	Spleno megaly	Age > 61 years WBC ≥ 15 × 10 ⁹ /l Thrombosis Abnormal karyotype Pruritus ^k	Age > 70 years WBC > 13 × 10 ⁹ /l Thrombosis	NR	None	Age < 60 years	Age > 65 years WBC > 25 × 10 ⁹ /l Thrombosis

Abbreviations: CMB, chlorambucil; Dx, diagnosis; HU, hydroxyurea; IFN, interferon; LT, leukemic transformation; MF, myelofibrosis; NR, not reported; WBC, white blood cell. ^aIncidence per 1000 person-years (95% CI). ^bIncidence of 31 (95% CI = 24.12–40.16) per 1000 person/year. ^cMedian time to leukemic or myelofibrotic transformation. ^dIncidence rate per 1000 person/year with 19% leukemic transformation from post-PV MF population (*n* = 63). ^eOverall mortality rate of 3.7 per 100 persons per year. ^fMedian overall survival 40% at 10 years. ^gMedian overall survival 14.1 years based on most mature follow-up cohort (*n* = 337). ^hMedian overall survival 72% at 10 years. ⁱ83% median overall survival at 10 years. ^jFavorable risk factor.

treatment regimens have also been linked to leukemic risk and will be discussed in greater detail below. Multivariate analysis has shown association of alkylating agents (pipobroman, P³², chlorambucil) and leukemia.^{3,11–13} In particular, exposure to P³², busulphan and pipobroman either alone or in combination has been linked to higher LT (HR of 5.46; 95% CI, 1.84–16.25, $P=0.0023$), with no LT risk associated with hydroxyurea (HU) usage alone (HR 0.86, 95% CI, 0.26–2.88, $P=0.8021$).¹² HU remains a standard cytoreduction therapy in PV, and it is important to recognize that HU resistance increases both LT and MF transformation risk (HR 6.8; 95% CI, 3.0–15.4%, $P<0.001$), whereas HU intolerance has no direct effect on outcomes.²⁷

POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF)

Post-ET MF is defined based on IWG-MRT consensus criteria requiring a previously documented WHO diagnosis of ET and the presence of bone marrow fibrosis (grade ≥ 2 on a 3-point scale or ≥ 3 on a 4-point scale). Two or more additional features are needed, including: anemia (with a ≥ 2 mg/l decrease from baseline), leukoerythroblastic peripheral blood findings, splenomegaly, elevated lactate dehydrogenase and ≥ 1 constitutional symptoms.¹⁰ Transformation to MF is less frequent in ET than PV and occurs late during the course of the disease.^{11,22,28} In larger cohort studies, the cumulative risk of post-ET MF is 3.9% at 10 years (incidence of 3.7×1000 person-years) and as high as 9.3% at 15 years. Table 3 summarizes rates of transformation among ET patients. Cumulative probabilities of fibrotic progression have been reported as 19.9% (5.6–12.6%) at 20 years.²⁸ Overall, the median time to myelofibrotic transformation is approximately 7–16 years from time of ET diagnosis.^{11,28–33} The variation of cumulative incidence rates of transformation in ET are attributed to discrepancies in diagnosis, in particular, distinguishing between primary ET and prefibrotic MF. Barbui *et al.*³⁴ compared the outcomes between confirmed ET and prefibrotic MF patients and identified that progression to overt MF at 10 and 15 years was 0.8% and 9.3%, compared with 12.3% and 16.9%, respectively. This correlates to a lower incidence of transformation of 0.5 per 100 patient-year in ET.³⁴ Risk factors for MF transformation include: age,³⁴ anemia,^{16,22,30,34} and bone marrow histopathology, including hypercellularity and increased reticulin.^{16,33,34} The influence of molecular markers such as *JAK2V617F* will be discussed in detail below. Additional studies have found that increased serum lactate dehydrogenase, increased leukocytosis and male gender are risks for myelofibrotic transformation.^{16,30,33}

POST-ESSENTIAL THROMBOCYTHEMIA ACUTE MYELOID LEUKEMIA

Earlier cohort studies of ET patients indicate that LT occurs at an incidence of 3×1000 person-years, with a cumulative risk of 2.6% at 10 years and 5.3% at 15 years.³⁰ Higher rates of transformation have been found in French, Spanish and Chinese studies, with 10-year rates of 8.3–9.7%.^{29,35,36} Conversely, much lower rates of LT have been identified as $<1\%$ at 10 years and 2% in 15 years.^{11,34} Again, this variability in findings has largely been attributed to discrepancies in morphological diagnosis between ET and prefibrotic PMF related to modifications in the 2001 WHO classification of ET to prefibrotic MF. Accordingly, Barbui *et al.*³⁴ confirmed ET in 891 patients based on the revised WHO criteria and found lower LT risks of 0.7% at 10 years and 2.1% at 15 years compared with 5.8% and 11.7% in the setting of early/prefibrotic PMF. In that particular study, prefibrotic PMF morphology, previous thrombosis and thrombocytosis ($>1000 \times 10^9/l$) were identified as risk factors.³⁴ Other risk factors for LT include: leukocytosis ($\geq 15 \times 10^9/l$),^{16,29} extreme thrombocytosis ($\geq 1000 \times 10^9/l$),^{34,37} anemia,^{16,22,37} older age (≥ 60 years),^{30,37}

reticulin grading, and bone marrow cellularity.^{16,34} Among the Mayo clinic cohort of 605 ET patients, anemia (Hgb <120 g/l in females, <135 g/l in males) and thrombocytosis ($\geq 1000 \times 10^9/l$) were found to be significant risk factors, and when incorporated into a prognostic model, patients with no risk factors had a 0.4% versus 6.5% (2 risk factors) rate of LT ($P=0.0009$).³⁷

THERAPY-RELATED RISKS OF DISEASE TRANSFORMATION

With the introduction of radiation treatment, in 1965, Modan and Lilienfeld observed that rates of PV-related LT were higher among X-ray-treated (8.9%) and P³²-treated (11%) patients than the non-radiated (1%) treatment groups.³⁸ Both the Polycythemia Vera Study Group (PVSG) and the French Polycythemia Study Group (FPSG) have also illustrated the leukemogenic potential of P³², with an incidence of 5–15% after 10 years of observation.^{38–40} In a large nested case-control study of MPN, AML/MDS development was significantly associated with P³² and alkylator exposure.⁴¹ Among alkylators, pipobroman has leukemogenic potential with actuarial leukemic risk of 14.4% and 18.7% at 10 and 15 years, respectively, reported among 164 PV patients.⁷ When investigating the role of low-dose aspirin in PV patients, the use of P³², pipobroman and busulphan independently had an impact on progression to AML/MDS in addition to the combination of either alkylating agent or P³² with HU; however, the use of HU alone was not found to be leukemogenic (HR 0.86; 95% CI, 0.26–2.88, $P=0.8021$).¹² The FPSG published their final results after a median follow-up of 16.3 years randomizing young PV patients (<65 years of age) to either first-line pipobroman or HU. In that study, the median survival was 17 years for the entire cohort compared with 20.3 years for those treated with HU and 15.4 years if received pipobroman ($P=0.008$) and differed significantly from age- and sex-matched general population. The cumulative incidence of LT was 6.6, 16.5 and 24% in the HU arm versus 13, 34 and 52% in the pipobroman arm ($P=0.004$) at 10, 15 and 20 years. This is despite patients being treated for longer durations in the HU arm (12 years) compared with pipobroman (9.5 years, $P<0.01$). When comparing single-agent therapy only (HU $n=94$, pipobroman $n=130$), the cumulative incidence of LT was 7.3, 10.7 and 16.6% compared with 14.6, 34 and 49.4% at 10, 15 and 20 years, respectively ($P=0.002$).⁴² This illustrates not only the leukemogenicity of pipobroman but also identifies the higher rates of LT with HU than previously reported in PV, which may or may not reflect the rate of natural evolution of the disease. In a large cohort of >1500 PV patients, multivariate analysis confirmed the association between LT and P³²/chlorambucil, pipobroman and pipobroman+HU/busulphan use. The use of HU or busulphan alone or in combination was not associated with leukemic risk.³ Likewise, cytoreductive agents unlike HU or interferon-alpha were associated with leukemic risk among the prospective multicenter PV study of 1638 patients.¹³ Although, HU treatment is not leukemogenic, therapy with ≥ 2 cytoreductive treatments carries an increased risk of LT (odds ratio (OR) 2.9; 95% CI, 1.4–5.9).⁴¹ It is important to consider the risks of additional therapy in the rare setting of HU intolerance or refractoriness when deciding on choices for alternative cytoreductive agents.

In contrast, the cumulative incidence of post-PV MF increases with HU at 15, 24 and 32% compared with 5, 10 and 21% using pipobroman ($P=0.02$) at 10, 15, and 20 years, respectively.⁴² Accordingly, sequential use of two or more myelosuppressive agents leads to higher incidences of MF compared with pipobroman use alone.¹¹ Although, PV patients receiving myelosuppressive agents had significantly higher MF transformation ($P=0.01$), they also had a significantly longer follow-up period compared with those treated with phlebotomy alone ($P<0.001$) and it was shown that longer follow-up also significantly led to higher rates of post-PV MF, thus making it difficult to conclude the effects of therapy on transformation.²¹

Table 3. Studies evaluating outcomes in essential thrombocythemia

	Passamonti et al. ¹¹	Chim et al. ²⁹	Wolanskyj et al. ²⁸	Gangat et al. ³⁷	Passamonti et al. ³⁰	Palandri et al. ³¹	Girodon et al. ³⁵	Abdulkarim et al. ¹⁶	Barbui et al. ³⁴	Malak et al. ³²	Tefferi et al. ²
<i>N</i>	435	231	322	605	605	386	311	130	891	105	292 (Mayo) 284 (Italy) 17.3 10.7
Median F/U (years)	9.3	NR	13.6	7	5.6	9.5	9.5	15	6.2	7.5	
<i>MF</i>											
<i>N</i>	1.6 (0.8–3.4) ^a	7 (3%)	NR ^b	NR	17 (2.8%)	20 (5%)	NR	7 (5%)	32 (4%)	12 (13%)	29 (9.9%) 26 (9.2%)
Median time to MF from Dx (years)	10.9	8	12.4	NR	9.1	7.25	NR	NR	NR	16	NR
Risk factors	NR	NR	None	NR	Anemia ^c	Sequential use of cytotoxic drugs	NR	Anemia Leukocytosis Reticulin BM cellularity	BM histology Age > 60 years Hgb < 120 g/l Absent JAK2V617F	None MPL mutated	
<i>Leukemia</i>											
<i>N</i>	1.2 (0.5–2.8) ^a	4 (1.7%)	NR ^d	20 (3.3%)	14 (2.3%)	6 (1.5%)	18 (5.8%)	11 (8%)	8 (1%)	7 (10%)	12 (4.1%) 4 (1.4%)
Median time to LT from Dx (years)	14.5	10	13.8	11.5	11	8.5	6.3	NR	NR	7.4	NR
Risk factors	None	Previous MF Melfalan WBC > 11 × 10 ⁹ /l	None	Anemia ^e Plts ≥ 1000 × 10 ⁹ /l Age (continuous variable)	Age > 60 years	Sequential use of cytotoxic drugs	None	Anemia Leukocytosis Reticulin BM cellularity	BM histology Thrombosis Plts > 1000 × 10 ⁹ /l	None	None
Median survival (years)	22.6	13	18.9	18	22.3	NR	11	NR ^f	14.7	NR ^g	19.8 ^h
Risk factors	Thrombosis Male	Age > 60 years	Age ≥ 60 years WBC ≥ 15 × 10 ⁹ /l Tobacco use DM	Age ≥ 60 years WBC ≥ 15 × 10 ⁹ /l Anemia ^e Thrombosis DM Smoking	Age > 60 years Thrombosis	Age ≥ 60 years WBC ≥ 15 × 10 ⁹ /l HTN DM Thrombosis	Age > 60 years WBC > 11 × 10 ⁹ /l Anemia	Anemia	Age > 60 years WBC > 11 × 10 ⁹ /l Hgb < 120 g/l Thrombosis BM histology	NR	Age ≥ 60 years

Abbreviations: BM, bone marrow; DM, diabetes mellitus; Dx, diagnosis; HTN, hypertension; HU, hydroxyurea; LT, leukemic transformation; MF, myelofibrosis; NR, not reported; Plts, platelets; WBC, white blood cell. ^aIncidence per 1000 person-years (95% CI). ^b3.8% cumulative probability of MF transformation at 10 years (95% CI = 1.4–6.1). ^cHgb < 125 g/l in females, < 135 g/l in males. ^d1.4% 10-year cumulative probability of AML transformation (95% CI = 0–3). ^eHgb < 120 g/l in females, < 135 g/l in males. ^fOverall survival 58% at 10 years. ^gOverall survival 83% at 10 years. ^hBased on Mayo cohort.

Few studies are available evaluating the efficacy and safety of cytoreductive agents in ET. Palandri *et al.*³¹ conducted a single-institution retrospective study on 386 ET patients with a median follow-up of 9.5 years (3–28.5 years) whereby 88% of the population received cytoreductive therapy. The evolution to AML and MF was 1.5% and 5%, respectively, and transformation was not influenced by the type of cytoreductive therapy: HU or busulphan. However, patients receiving sequential therapy were at higher risk for AML/MDS compared with single-therapy use ($P=0.0039$), and no disease transformation occurred among patients without treatment or if exposed to interferon alone.³¹ Anagrelide has been linked to post-ET MF, when compared with HU in the PT-1 trial and used in combination with aspirin (OR 2.92, 95% CI, 1.24–6.86, $P<0.01$).⁴³ Duration of anagrelide use (>60 months) posed a higher risk for transformation (OR 9.32; 95% CI, 1.1–78.5, $P<0.01$).⁴⁴ However, no differences were found in the ANAHYDRET study that evaluated WHO–ET diagnosed patients compared with the UK-PT1 study, which based ET on PVSG criteria.⁴⁵ Finally, melphalan exposure has been associated with increased risk of evolution to AML among ET patients although it is not a commonly used therapy.²⁹

Overall, there is no confirmed consensus implicating HU, anagrelide or busulphan as leukemogenic agents in PV or ET. The two largest non-controlled studies in ET³⁷ and PV¹² did not identify a risk of LT related to HU. Likewise, interferon- α has not been clearly implicated with transformation.^{31,46,47} The associations of higher transformation risk related to combination or sequential therapy are not clear and may be representative of more aggressive disease requiring more therapy with ultimately higher risk of progression. It is not well understood what influence chronic therapy has on the acquisition of genetic aberrations related to MPN and their associated risk to transformation. Genetic mutations leading to drug resistance may also have a role in disease transformation whereby the presence of p53 mutations may have suspected involvement in this process.⁴⁸

PROGNOSTIC IMPLICATIONS OF THE *JAK2V617F* MUTATION OR ITS ALLELE BURDEN

Under normal circumstances, a polyclonal stem cell pool is responsible for hematopoiesis. In the setting of MPN, acquired mutations in hematopoietic stem cells lead to abnormal monoclonal or oligoclonal hematopoiesis. Additional genetic mutations may alter clinical phenotype pattern of each MPN, and during course of the disease, further genetic alterations can occur that promote disease progression and/or transformation.⁴⁸ A major advance in understanding the pathogenesis of MPN was made with the discovery of the gain-of-function Janus kinase-2 (*JAK2V617F*) mutation in 2005.^{49–51} The most prevalent mutation in MPN is the *JAK2V617F* mutation on exon 14, which is present in 95% of PV and 50–60% of ET patients conferring a constitutive tyrosine kinase activity.^{49,50,52} Variable proportions of *JAK2V617F* mutant alleles are found in myeloid cell populations.⁵³ The *JAK2V617F* mutation can be present in a heterozygous or a homozygous state, with the latter representing a mitotic recombination event resulting in uniparental disomy.⁵⁴ Homozygosity is frequent in PV (25%) that contributes to their higher mutant allele burden.^{54,55}

A mutant allele dosage effect on clinical phenotype has been described in PV, whereby higher mutant allele burden correlates with higher severity of disease.^{55–57} Retrospective studies have identified that patients homozygous for *JAK2V617F* mutations are more likely to progress to post-PV MF.^{56–58} Rates of fibrotic transformation have been found to be 11.5% versus 1.4%⁵⁵ and 23% versus 2%⁵⁹ for homozygous compared with heterozygous *JAK2* mutants, respectively. In a study of 647 patients, 68 evolved to post-PV MF, with 78% at the time of evolution having mutant allele burdens of $>50\%$.²¹ Similarly, Passamonti *et al.*¹⁵ identified

320 PV patients (median follow-up of 3.2 years) in whom a mutant allele burden $\geq 50\%$ was a significant risk factor for MF transformation. *JAK2V617F* allele burdens of $\geq 50\%$ have been associated with elevated white blood cell ($P=0.034$), thrombocytosis ($P=0.010$) and, accordingly, higher incidence of both thrombosis ($P=0.032$) and post-PV MF ($P=0.018$).²⁰ Interestingly, in a study of 97 PV patients, 21% had MF transformation, and 22% developed leukemia whereby *JAK2V617F* allele burden ($>50\%$) was associated with MF transformation ($P<0.0001$) but not leukemogenesis.³² Higher *JAK2V617F* allele burdens of $>80\%$ also correlated with advanced MF and greater splenomegaly.⁶⁰ However, it should be noted that association of allelic burden and transformation, particularly risks of leukemic evolution, are not consistent in PV.^{19,61}

Among ET patients, 14.3% of homozygous patients for the *JAK2V617F* mutation developed MF as compared with 4.7% of heterozygous patients ($P=0.011$) or 1.6% of wild-type patients ($P=0.001$).⁵⁷ In an evaluation of ET patients based on revised WHO criteria, Gangat *et al.*³⁷ identified that the presence of *JAK2V617F* did not predict LT or inferior survival. In one of the largest ET studies comparing *JAK2V617F* mutated ($n=414$) to unmutated cases ($n=362$), there was no significant difference in survival, leukemic or MF transformation rates.⁶² Other studies confirmed the lack of correlation related to *JAK2* mutational status and disease transformation.^{32,63,64} Interestingly, in a large multicenter study by Barbui *et al.*³⁴ the presence of *JAK2V617F* mutation significantly decreased the rate of MF progression (HR 0.37; 95% CI, 0.17–0.79, $P=0.15$) among ET patients but did not influence LT or overall survival. Finally, in comparing chronic phase to BP MPN, including both PV and ET, there was no statistical association between the time of LT or overall survival and *JAK2V617F* status. There is 20% less incidence of *JAK2V617F* mutations in BP MPN versus chronic phase MPN.⁶⁵ In fact, it is not uncommon to find isolated acute leukemic clones to have reverted to a *JAK* wild-type status at the time of transformation.^{66,67} Overall, *JAK2V617F* presence is not a prerequisite for LT and more likely additional genetic events are required in the setting of disease transformation.⁶⁵

MUTATIONS INFLUENCING DISEASE TRANSFORMATION

Following the discovery of *JAK2V617F* mutation, additional somatic mutations have been found and implicated in MPN pathogenesis, particularly in cases of *JAK2*-negative disease (Table 4). *MPL* is found at chromosome 1p34 and encodes the thrombopoietin receptor, which mediates signaling via the *JAK*–*STAT* (signal transducer and activator of transcription factor) pathway. *MPL*-acquired mutations (that is, *W515L*, *W515K*) occur in both ET and PMF, with approximately 1–4% in ET patients and mutually exclusive from *JAK2V617F*.^{68–70} Based on a population frequency of 6% in a MPN cohort study, *MPL* mutation status did not impact time to LT or overall survival.⁶⁵ Additional studies have shown its lack of impact on post-ET MF or LT risk.^{69,70} In a longer follow-up study, higher rates of post-ET MF, leukemia and lower overall survival rates occurred in *MPL*-mutated ET (3%, $n=8$) when compared with those with *JAK2* or *CALR* mutations.⁷¹ *CALR* mutations are rare in PV but occur in approximately 15–32%^{71–73} of ET cases, with higher incidences (49–71%) in *JAK2/MPL* unmutated ET.^{72,74,75} *CALR* is located on chromosome 19p13.2 and is a multi-functional Ca^{2+} -binding protein chaperone.⁷⁶ In a recent follow-up study of 299 ET patients over 12.7 years, *CALR* mutations versus *JAK2V617F* mutations were associated with younger age ($P=0.002$), male sex ($P=0.01$), higher platelet count ($P=0.0004$), lower hemoglobin ($P<0.0001$), lower leukocytosis ($P=0.02$) and lower thrombosis rates ($P=0.04$). Between the two mutational groups, LT and myelofibrotic transformation rates were not significantly different ($P=0.28$).⁷¹ In other studies, the *CALR* mutation has been associated with decreased or equal incidence

Table 4. Intrinsic risk factors for disease transformation in PV and ET

Transformation	Clinical risk factors	Genetic risk factors
Post-PV MF	Age Leukocytosis Disease duration Reticulin fibrosis Splenomegaly	<i>JAK2V617F</i> allele burden
Post-PV Leukemia	Age Leukocytosis Reticulin fibrosis Splenomegaly	Abnormal karyotype <i>TP53</i> <i>RUNX1</i>
Post-ET MF	Age Leukocytosis Anemia Reticulin fibrosis	Absent <i>JAK2V617F</i> mutation <i>ASXL1</i>
Post-ET leukemia	Age Leukocytosis Anemia Reticulin fibrosis Thrombosis Platelets $\geq 1000 \times 10^9/l$	<i>TP53</i> <i>RUNX1</i>

Abbreviations: ET, essential thrombocythemia; MF, myelofibrosis; PV, polycythemia vera.

of LT,^{73,77} with no clear association with post-ET MF.^{72,73} The role of *LNK* (*SH2B3*), an adaptor protein that is a negative regulator of thrombopoietin–*MPL*-mediated *JAK* activation pathway, is unclear. *LNK* mutations are associated with expansion of the myeloid progenitor precursors through the *JAK*–*STAT* pathway. In an analysis of 61 patients, *LNK* mutations were present in 9.8% of BP samples and were rare in chronic phase, suggesting that this mutation may be linked to leukemogenesis; however, they were not mutually exclusive of other MPN mutations and a direct genotype–phenotype correlation could not be concluded.⁷⁸

Transcription factors have an important role in gene expression regulation and are often mutated in the setting of MPN. The gene encoding the Ikaros transcription factor (*IKZF1*) was shown in MPN to be the target of chromosome 7p deletions, with loss of *IKZF1* associated with LT.⁷⁹ An important transcription factor that is responsible for cell cycle regulation and DNA damage response is p53 (encoded by *TP53* gene), a tumor-suppressor protein that has been implicated in LT in MPN.^{80–82} Among 22 patients with post-MPN AML, 45.5% had a form of p53 mutation.⁸² In analyzing post-MPN AML, the presence of p53 mutations was an adverse prognostic factor for overall survival (HR 2.67; 95% CI, $P = 0.006$).⁸³ Likewise, the *RUNX1/AML1* gene encodes a transcription factor involved in hematopoiesis, and mutations are linked to LT in MPNs.^{51,80,84} Finally, splicing factors have also been implicated with recurrent mutations in *SRSF2*, *ZRSF2*, *U2AF1* and *SF3B1* identified among 22 MPN patients with leukemia.⁸⁵

In MPN-BP, genomic alterations are threefold ($P < 0.001$) more abundant compared with chronic phase.⁶⁵ The spectrum of mutations in MPN-derived leukemia differs from *de novo* AML where in the latter we commonly see mutations in *FLT3*, *NPM1* and *DNMT3a*.^{83,86,87} In post-MPN AML, gene sequencing studies have identified frequent mutations in epigenetic regulators such as ten-eleven translocation 2 (*TET2*), additional sex combs-like (*ASXL1*) and isocitrate dehydrogenase (*IDH1/2*) at the time of LT.^{81,85,88,89} Rampal *et al.*⁸¹ identified additional mutations using high-throughput sequence analysis on post-MPN AML patients, including: *CALR*, *MYC*, *PTPN11* and *SETBP1*. In *JAK2V617F*-mutated subgroups, common co-occurring mutations were *TP53* (44%), *ASXL1* (44%) and *IDH2* (44%), whereas *CALR* (43%), *ASXL1* (38%) and *SRSF2* tended to occur in *JAK2* wild type post-MPN. *TET*

enzymes catalyze conversion of 5-methylcytosine to 5-hydroxymethylcytosine, which leads to DNA methylation. The frequency of *TET2* mutations are 5% in ET and 16% in PV patients.⁹⁰ The incidence of *TET2* mutations in MPN-BP has been reported as 17%, but the presence of the mutation among PV and PMF patients did not seem to affect LT or survival rates.⁹⁰ The enzymes *IDH1/2* catalyze the conversion of isocitrate to alpha-ketoglutarate, which acts as a co-factor for *TET2* whereby intact *IDH* activity is important for protection against oxidative stress.⁵¹ Mutations of *IDH1* and *IDH2* cause inhibition of *TET2* activity, lead to decreased DNA methylation and impaired hematopoietic differentiation.⁹¹ There is a low incidence of *IDH1/2* mutations in PV (1.9%) and ET (0.8%); however, in MPN-BP, *IDH* mutations are as high as 21.6%, suggesting an association with LT ($P < 0.01$) and confer a worse survival ($P = 0.01$).⁹² Finally, *ASXL1* is a nuclear polycomb protein with mutations found on chromosome 20q1.1 that affect the regulation of transcription and RAR-mediated signaling. *ASXL1* mutations are rare in ET and PV but are most frequently found in post-ET MF and may be related to its pathogenesis.⁹³

CYTOGENETIC RISK FACTORS

It is anticipated that our expanding knowledge of the genetic profiles of MPN will have an important role in predicting disease outcomes. Tefferi *et al.*³ showed for the first time the prognostic relevance of karyotype in an international PV study. Similarly, Dingli *et al.*⁹⁴ illustrated that cytogenetic findings likely superseded disease-related characteristics such as age and anemia for predicting survival among PV and ET patients with secondary MF. Frequently reported karyotype abnormalities in MPN-BP are complex often involving chromosomes 1, 9, 5 and 7 abnormalities.^{8,19,84,95,96} In general, cytogenetic abnormalities are estimated in 15% of PV patients.^{19,61} Among transformed PV patients, with no prior treatment exposures aside from phlebotomy, the most frequent cytogenetic abnormalities included: +1q, +8, +9, and 20q–.⁹⁶ In ET, most patients have a normal karyotype at the time of diagnosis, with an overall prevalence of cytogenetic anomalies being <10%.^{97–99} Despite having abnormal cytogenetics at the time of diagnosis, ET patients do not have shorter survival or higher risks of myelofibrotic transformation or LT.⁹⁷ At the time of LT, most patients have a detectable abnormality.^{97,98,100} Overall, single-nucleotide polymorphism arrays have identified changes of chromosomes 1q, 7q, 5q, 6p, 7p, 16q, 19q, 21q, 22q and 3q associated with post-MPN AML.^{65,84} High-resolution single-nucleotide polymorphism arrays have identified established targets relating to disease progression that include: *MYC* (chromosome 8), *ETV6* (chromosome 12), *TP53* (chromosome 17), and *RUNX1* (chromosome 21).^{65,84} Clearly, in other myeloid malignancies and in primary MF, cytogenetics has an important role in prognosis, and currently our knowledge of its implication in PV and ET is expanding. Ultimately, with new technologic advancements, identifying candidate genes involved in transformation of both PV and ET into MF and AML/MDS can provide insight into the complex pathogenesis of MPN and assist in the development of therapeutic targets for prevention of transformation.

CONCLUSION

Both PV and ET are *BCR-ABL1*-negative MPN with increased morbidity and mortality mainly attributed to thrombohemorrhagic complications with progression to AML and MF leading to a dismal prognosis, particularly in the setting of LT where median survival is significantly shortened to <6 months. Allogeneic stem cell transplantation remains the only curative option in few eligible patients and new therapeutic agents remain in development. The underlying mechanism for transformation to either MF or BP remains unclear and is likely multifactorial. There is a need to

improve the identification of high-risk patients. Understanding the genetic mutations that lead to disease progression and transformation is a current research focus, and with advancements in genetic profiling, the pathogenesis of MPN will become even more complex. It is anticipated that establishing genetic profiles within MPN will allow better classification of patients to improve clinical management and treatment.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

SC and AT conceived and designed the work that led to submission. SC drafted the initial manuscript. SC and AT both edited and approved the final version of the manuscript.

REFERENCES

- Spivak JL. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. *Semin Hematol* 2004; **41**: 1–5.
- Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L *et al*. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. *Blood* 2014; **124**: 2507–2513.
- Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi A, Rodeghiero F *et al*. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. *Leukemia* 2013; **27**: 1874–1881.
- Passamonti F, Thiele JJ, Girodon F, Rumi E, Carobbio A, Gisslinger H *et al*. A prognostic model to predict survival in 867 World Health Organization – defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. *Blood* 2012; **120**: 1197–1201.
- Dunphy CH, Kitchen S, Saravia O, Velasquez WS. Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature. *Am J Hematol* 1996; **51**: 85–89.
- Polliack A, Prokocimer M, Matzner Y. Lymphoblastic leukemic transformation (lymphoblastic crisis) in myelofibrosis and myeloid metaplasia. *Am J Hematol* 1980; **9**: 211–220.
- Kiladjian J-J, Gardin C, Renoux M, Bruno F, Bernard J-F. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. *Hematol J* 2003; **4**: 198–207.
- Tam CS, Nussenzweig RM, Popat U, Bueso-Ramos CE, Deborah A, Cortes JA *et al*. The natural history and treatment outcome of blast phase BCR-ABL myeloproliferative neoplasms. *Blood* 2008; **112**: 1628–1637.
- Kennedy JA, Atenafu EG, Messner HA, Craddock KJ, Brandwein JM, Lipton JH *et al*. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. *Blood* 2013; **121**: 2725–2733.
- Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S *et al*. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. *Leukemia* 2008; **22**: 437–438.
- Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M *et al*. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. *Am J Med* 2004; **117**: 755–761.
- Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C *et al*. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. *Blood* 2005; **105**: 2664–2670.
- Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C *et al*. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. *J Clin Oncol* 2005; **23**: 2224–2232.
- Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythemia vera predicts both inferior survival and leukaemic transformation. *Br J Haematol* 2007; **138**: 354–358.
- Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L *et al*. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. *Leukemia* 2010; **24**: 1574–1579.
- Abdulkarim K, Ridell B, Johansson P, Kutti J, Safai-Kutti S, Andréasson B. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. *Eur J Haematol* 2010; **86**: 148–155.
- Bonicelli G, Abdulkarim K, Mounier M, Johansson P, Rossi C, Jooste V *et al*. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythemia vera: a population-based study of 327 patients. *Br J Haematol* 2013; **160**: 251–254.
- Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D *et al*. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. *Leuk Lymphoma* 2013; **54**: 1989–1995.
- Sever M, Quintás-Cardama A, Pierce S, Zhou L, Kantarjian H, Verstovsek S. Significance of cytogenetic abnormalities in patients with polycythemia vera. *Leuk Lymphoma* 2013; **54**: 2667–2670.
- Bai J, Ai L, Zhang L, Yang F, Zhou Y, Xue Y. Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. *Am J Hematol* 2015; e-pub ahead of print 15 September 2015; doi:10.1002/ajh.24191.
- Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E *et al*. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. *Blood* 2008; **111**: 3383–3387.
- Tefferi A, Gangat N, Wolanskyj AP, Schwager S, Pardanani A, Lasho TL *et al*. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. *Eur J Haematol* 2008; **80**: 386–390.
- Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E *et al*. Masked polycythemia Vera (mPV): results of an international study. *Am J Hematol* 2014; **89**: 52–54.
- Tiribelli M, Barraco D, De Marchi F, Marin L, Medeot M, Damiani D. Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera. *Ann Hematol* 2014; **12**: 14–15.
- Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML *et al*. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. *Blood* 2012; **119**: 2239–2241.
- Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. *Br J Haematol* 2000; **110**: 577–583.
- Alvarez-Larrán A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernández-Boluda JC, Ferrer-Marín F *et al*. Assessment and prognostic value of the European Leukemia Net criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. *Blood* 2012; **119**: 1363–1369.
- Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. *Mayo Clin Proc* 2006; **81**: 159–166.
- Chim C-S, Kwong Y-L, Kwok-Wei A, Ma S-K, Chan C-C, Wong L-G *et al*. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. *Arch Intern Med* 2005; **165**: 2651–2658.
- Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D *et al*. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. *Haematologica* 2008; **93**: 1645–1651.
- Palandri F, Catani L, Testoni N, Ottaviani E, Polverelli N, Fiacchini M *et al*. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. *Am J Hematol* 2009; **84**: 215–220.
- Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. *Blood Cells Mol Dis* 2012; **49**: 170–176.
- Alvarez-Larrán A, Cervantes F, Bellosillo B, Giral M, Juliá A, Hernández-Boluda JC *et al*. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. *Leukemia* 2007; **21**: 1218–1223.
- Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M *et al*. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. *J Clin Oncol* 2011; **29**: 3179–3184.
- Girodon F, Dutrillaux F, Broséus J, Mounier M, Goussot V, Bardonnaud P *et al*. Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients. *Leukemia* 2010; **24**: 900–903.
- Cervantes F, Alvarez-Larrán A, Talam C, Gómez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. *Br J Haematol* 2002; **118**: 786–790.
- Gangat N, Wolanskyj AP, McClure RF, Li C-Y, Schwager S, Wu W *et al*. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. *Leukemia* 2007; **21**: 270–276.

- 38 Björkholm M, Hultcrantz M, Derolf ÅR. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated? *Best Pract Res Clin Haematol* 2014; **27**: 141–153.
- 39 Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT *et al*. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. *N Engl J Med* 1981; **304**: 441–447.
- 40 Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. *Blood* 1997; **89**: 2319–2327.
- 41 Björkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR *et al*. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. *J Clin Oncol* 2011; **29**: 2410–2415.
- 42 Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. *J Clin Oncol* 2011; **29**: 3907–3913.
- 43 Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D *et al*. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. *N Engl J Med* 2005; **353**: 33–45.
- 44 Mela Osorio MJ, Ferrari L, Goette NP, Gutierrez MI, Glembotsky AC, Maldonado AC *et al*. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status. *Eur J Haematol* 2015; e-pub ahead of print 19 July 2015; doi:10.1111/ejh.12614.
- 45 Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kralovics R *et al*. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. *Blood* 2013; **121**: 1720–1728.
- 46 Fruchtman SM, Pettitt RM, Gilbert HS, Fiddler G, Lyne A. Anagrelide Study Group. Analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. *Leuk Res* 2005; **29**: 481–491.
- 47 Gowin K, Thapaliy P, Samuelson J, Harrison C, Radia D, Andreasson B *et al*. Experience with pegylated interferon α -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. *Haematologica* 2012; **97**: 1570–1573.
- 48 Them NCC, Kralovics R. Genetic basis of MPN: beyond JAK2-V617F. *Curr Hematol Malig Rep* 2013; **8**: 299–306.
- 49 Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR *et al*. A gain-of-function mutation of JAK2 in myeloproliferative disorders. *N Engl J Med* 2005; **352**: 1779–1790.
- 50 James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C *et al*. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. *Nature* 2005; **434**: 1144–1148.
- 51 Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. *Blood* 2011; **118**: 1723–1735.
- 52 Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S *et al*. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet* 2005; **365**: 1054–1061.
- 53 Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C *et al*. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. *Blood* 2006; **107**: 3676–3682.
- 54 Alshemari SH, Rajaan R, Ameen R, Al-Drees MA, Almosaileh MR. JAK2V617F allele burden in patients with myeloproliferative neoplasms. *Ann Hematol* 2014; **93**: 791–796.
- 55 Vannucchi A, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V *et al*. Prospective identification of high-risk polycythemia vera patients based on JAK2 (V617F) allele burden. *Leukemia* 2007; **21**: 1952–1959.
- 56 Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R *et al*. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2 V617F in polycythemia vera. *Cancer* 2006; **106**: 631–635.
- 57 Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Marchioli R, Marfisi RM *et al*. Clinical profile of homozygous JAK2V617V>F mutation in patients with polycythemia vera or essential thrombocythemia. *Blood* 2007; **110**: 840–846.
- 58 Alvarez-Larrán A, Bellosillo B, Martínez-Avilés L, Saumell S, Salar A, Abella E *et al*. Postpolycythemic myelofibrosis: frequency and risk factors for this complication in 116 patients. *Br J Haematol* 2009; **146**: 504–509.
- 59 Tefferi A, Strand JJ, Lasho TL, Knudson RA, Finke CM, Gangat N *et al*. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. *Leukemia* 2007; **21**: 2074–2075.
- 60 Silver RT, Vandriss K, Wang YL, Adriano F, Jones AV, Christos PJ *et al*. JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. *Leuk Res* 2011; **35**: 177–182.
- 61 Gangat N, Strand J, Lasho TL, Finke CM, Knudson RA, Pardanani A *et al*. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. *Eur J Haematol* 2008; **80**: 197–200.
- 62 Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT *et al*. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2 V617F mutation status: a prospective study. *Lancet* 2005; **366**: 1945–1953.
- 63 Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP *et al*. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. *Cancer* 2007; **109**: 2279–2284.
- 64 Palandri F, Ottaviani E, Salmi F, Catani L, Polverelli N, Fiacchini M *et al*. JAK2V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. *Leuk Lymphoma* 2009; **50**: 247–253.
- 65 Thoenissen NH, Krug UO, Lee DHT, Kawamata N, Iwanski GB, Lasho T *et al*. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. *Blood* 2010; **115**: 2882–2890.
- 66 Theodorides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E *et al*. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. *Blood* 2007; **110**: 375–379.
- 67 Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJP *et al*. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. *Blood* 2006; **108**: 3548–3555.
- 68 Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M *et al*. MPLS15 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. *Blood* 2006; **108**: 3472–3476.
- 69 Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D *et al*. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. *Blood* 2008; **112**: 141–149.
- 70 Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G *et al*. Characteristics and clinical correlates of MPL S15W > L/K mutation in essential thrombocythemia. *Blood* 2008; **112**: 844–847.
- 71 Tefferi A, Wasse E, Lasho T, Finke C, Belachew A, Ketterling R *et al*. Calreticulin mutations and long-term survival in essential thrombocythemia. *Leukemia* 2014; **28**: 2300–2303.
- 72 Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Fanelli T *et al*. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. *Blood* 2014; **123**: 1552–1556.
- 73 Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Jelena D *et al*. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. *Blood* 2014; **123**: 1544–1551.
- 74 Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD *et al*. Somatic mutations of calreticulin in myeloproliferative neoplasms. *N Engl J Med* 2013; **369**: 2379–2390.
- 75 Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC *et al*. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. *N Engl J Med* 2013; **369**: 2391–2405.
- 76 Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. *Leukemia* 2014; **28**: 1407–1413.
- 77 Andrikovics H, Kraling T, Balassa K, Halm G, Bors A, Koszarska M *et al*. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. *Haematologica* 2014; **99**: 1184–1190.
- 78 Pardanani A, Lasho T, Finke C, Oh ST, Gottlieb J, Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. *Leukemia* 2010; **24**: 1713–1718.
- 79 Jäger R, Gisslinger H, Passamonti F, Rumi E, Berg T, Gisslinger B *et al*. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. *Leukemia* 2010; **24**: 1290–1298.
- 80 Beer PA, Delhommeau F, LeCouédic JP, Dawson MA, Chen E, Bareford D *et al*. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. *Blood* 2010; **115**: 2891–2900.
- 81 Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D *et al*. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. *Proc Natl Acad Sci* 2014; **111**: E5401–E5410.
- 82 Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 lesions in leukemic transformation. *N Engl J Med* 2011; **364**: 488–490.
- 83 Milosevic JD, Puda A, Malcovati L, Berg T, Hofbauer M, Stukalov A *et al*. Clinical significance of genetic aberrations in secondary acute myeloid leukemia. *Am J Hematol* 2012; **87**: 1010–1016.
- 84 Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K *et al*. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. *Blood* 2011; **118**: 167–176.
- 85 Zhang S, Rampal R, Manshoury T, Patel J, Mensah N, Kayserian A *et al*. Genetic analysis of patients with leukemic transformation of myeloproliferative

- neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. *Blood* 2012; **119**: 4480–4485.
- 86 Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson AG *et al.* Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia The Cancer Genome Atlas Research Network. *N Engl J Med* 2013; 2059–2074.
 - 87 Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J *et al.* Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *N Engl J Med* 2012; **366**: 1079–1089.
 - 88 Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. *N Engl J Med* 2010; **362**: 369–370.
 - 89 Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C *et al.* Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. *Cancer Res* 2010; **70**: 447–452.
 - 90 Tefferi A, Pardanani A, Lim K-H, Abdel-Wahab O, Lasho TL, Patel J *et al.* TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. *Leukemia* 2009; **23**: 905–911.
 - 91 Figueroa ME, Wahab OA, Lu C, Ward PS, Patel J, Shih A *et al.* Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell* 2010; **18**: 553–567.
 - 92 Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D *et al.* IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. *Leukemia* 2010; **24**: 1302–1309.
 - 93 Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL *et al.* Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. *Haematologica* 2011; **96**: 1462–1469.
 - 94 Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. *Cancer* 2006; **106**: 1985–1989.
 - 95 Passamonti F, Rumi E, Arcaini L, Castagnola C, Lunghi M, Bernasconi P *et al.* Leukemic transformation of polycythemia vera: a single center study of 23 patients. *Cancer* 2005; **104**: 1032–1036.
 - 96 Swolin B, Rödger S, Westin J. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera. *Ann Hematol* 2008; **87**: 467–474.
 - 97 Gangat N, Tefferi A, Thanarajasingam G, Patnaik M, Schwager S, Ketterling R *et al.* Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. *Eur J Haematol* 2009; **83**: 17–21.
 - 98 Sessarego M, Defferrari R, Dejana AM, Rebutato AM, Fugazza G, Salvidio E *et al.* Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study. *Cancer Genet Cytogenet* 1989; **43**: 57–65.
 - 99 Panani AD. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications. *Cancer Lett* 2007; **255**: 12–25.
 - 100 Panani AD. Cytogenetic findings in untreated patients with essential thrombocythemia. *In Vivo* 2006; **20**: 381–384.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>